Status:
UNKNOWN
Study Evaluating Denosumab on Vascular and Bone Metabolism in Osteoporotic Chronic Kidney Disease (HDENOBS)
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Osteoporosis
Chronic Kidney Disease 5D
Eligibility:
All Genders
18+ years
Brief Summary
Aim of this study is to evaluate in a population of osteoporotic chronic kidney disease patients the effect of denosumab: * on coronary artery calcification scores evolution after 24 months of follow...
Detailed Description
Aim of this study is to evaluate in a population of osteoporotic chronic kidney disease patients the effect of denosumab: * on coronary calcification scores evolution (by multidetector computed tomog...
Eligibility Criteria
Inclusion
- Chronic kidney disease stage 5D patient, hemodialyzed with extracorporeal treatment for at least 3 months
- Osteoporosis
Exclusion
- Pregnancy or breastfeeeding female
- Current corticoid treatment
- PTH and Calcium outside the KDIGO guidelines
- Adynamic bone disease suspicion
- Cancer or myeloma
- Serious hepatic cytolysis
- Serious dental troubles
- Positive HIV serology
- Hypersensibility to active substance or one of excipients of denosumab
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT05234047
Start Date
May 1 2022
End Date
February 1 2025
Last Update
April 14 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.